Eesti - eesti - Ravimiamet

aspen pharma trading limited - kloorambutsiil - õhukese polümeerikattega tablett - 2mg 25tk

Eesti - eesti - Ravimiamet

aspen pharma trading limited - melfalaan - õhukese polümeerikattega tablett - 2mg 25tk

Eesti - eesti - Ravimiamet

aspen pharma trading limited - bupivakaiin - süstelahus - 5mg 1ml 4ml 5tk

Eesti - eesti - Ravimiamet

aspen pharma trading limited - melfalaan - süstelahuse pulber ja lahusti - 50mg 1tk

Eesti - eesti - Ravimiamet

aspen pharma trading limited - merkaptopuriin - tablett - 50mg 25tk

Eesti - eesti - Ravimiamet

aspen pharma trading limited - asatiopriin - õhukese polümeerikattega tablett - 50mg 100tk

Eesti - eesti - Ravimiamet

aspen pharma trading limited - busulfaan - õhukese polümeerikattega tablett - 2mg 100tk

Eesti - eesti - Ravimiamet

aspen pharma trading limited - desogestreel+etünüülöstradiool - tablett - 25mcg+40mcg/125mcg+30mcg 21tk / 45tk; 25mcg+40mcg/125mcg+30mcg 7tk / 15tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).